Dual-Ligase Strategy Adds New Layer of Control to Targeted Protein Degradation

Key Takeaways

• Dual-ligase degrader targets SMARCA2/4 in BAF complex
• Molecule can recruit two distinct E3 ligases for protein clearance
• Both pathways must be disabled to stop degradation, providing redundancy
• Small chemical tweaks shift ligase preference, enabling tunable degradation
• Strategy may curb resistance in cancer therapies by adding robustness

Pulse Analysis

Targeted protein degradation (TPD) has emerged as a transformative modality in drug discovery, allowing scientists to eliminate disease‑causing proteins rather than merely inhibiting their activity. By linking a target protein to an E3 ubiquitin ligase, degraders trigger ubiquitination and subsequent proteasomal destruction, opening therapeutic windows for previously “undruggable” targets such as transcription factors and scaffolding proteins. However, most clinical candidates rely on a single ligase, typically CRBN or VHL, creating a single point of failure when cancer cells mutate or down‑regulate that pathway. Overcoming this vulnerability has become a priority for the field.

The new study from CeMM, AITHYRA and the Centre for Targeted Protein Degradation demonstrates a small molecule that can bind both SMARCA2/4 and two different E3 ligases, effectively providing a built‑in backup system. Genetic knock‑out of either ligase leaves degradation intact, while simultaneous disruption of both aborts the process. Cryo‑EM and biophysical assays showed that subtle changes to the degrader’s linker region shift its affinity from one ligase to the other, offering medicinal chemists a tunable handle to bias pathway selection without redesigning the entire scaffold.

From a commercial perspective, dual‑ligase degraders could dramatically extend the durability of oncology pipelines, where resistance driven by ligand‑receptor alterations is a leading cause of trial failure. By distributing the ubiquitination workload across multiple ligases, tumors would need to acquire multiple, independent mutations to escape therapy, a statistically unlikely event. The concept also broadens the pool of exploitable E3 ligases, encouraging the discovery of tissue‑specific or disease‑selective ligases that further improve safety profiles. As the TPD toolbox expands, investors and biotech firms are likely to prioritize platforms that embed redundancy and tunability at the molecular level.